Gritstone Bio Inc (NASDAQ: GRTS) has seen a decline in its stock price by -4.18 in relation to its previous close of 0.61. However, the company has experienced a -0.19% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-30 that –Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA subgroup where events accrue more slowly
Is It Worth Investing in Gritstone Bio Inc (NASDAQ: GRTS) Right Now?
The 36-month beta value for GRTS is also noteworthy at 0.49. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for GRTS is 110.21M, and at present, short sellers hold a 6.02% of that float. The average trading volume of GRTS on October 01, 2024 was 1.22M shares.
GRTS’s Market Performance
GRTS’s stock has seen a -0.19% decrease for the week, with a 28.24% rise in the past month and a -0.02% fall in the past quarter. The volatility ratio for the week is 6.75%, and the volatility levels for the past 30 days are at 8.50% for Gritstone Bio Inc The simple moving average for the past 20 days is 7.86% for GRTS’s stock, with a -55.67% simple moving average for the past 200 days.
Analysts’ Opinion of GRTS
Many brokerage firms have already submitted their reports for GRTS stocks, with JMP Securities repeating the rating for GRTS by listing it as a “Mkt Outperform.” The predicted price for GRTS in the upcoming period, according to JMP Securities is $4 based on the research report published on February 28, 2024 of the current year 2024.
B. Riley Securities gave a rating of “Buy” to GRTS, setting the target price at $8 in the report published on March 28th of the previous year.
GRTS Trading at 6.84% from the 50-Day Moving Average
After a stumble in the market that brought GRTS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.59% of loss for the given period.
Volatility was left at 8.50%, however, over the last 30 days, the volatility rate increased by 6.75%, as shares surge +21.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.78% lower at present.
During the last 5 trading sessions, GRTS fell by -0.19%, which changed the moving average for the period of 200-days by -63.30% in comparison to the 20-day moving average, which settled at $0.5428. In addition, Gritstone Bio Inc saw -71.57% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GRTS starting from Allen Andrew R, who sale 24,263 shares at the price of $0.75 back on May 16 ’24. After this action, Allen Andrew R now owns 985,360 shares of Gritstone Bio Inc, valued at $18,156 using the latest closing price.
Jones Erin, the EVP, CHIEF OPERATING OFFICER of Gritstone Bio Inc, sale 13,749 shares at $0.75 during a trade that took place back on May 16 ’24, which means that Jones Erin is holding 359,293 shares at $10,288 based on the most recent closing price.
Stock Fundamentals for GRTS
Current profitability levels for the company are sitting at:
- -87.87 for the present operating margin
- -3.25 for the gross margin
The net margin for Gritstone Bio Inc stands at -78.25. The total capital return value is set at -1.26. Equity return is now at value -201.94, with -72.86 for asset returns.
Based on Gritstone Bio Inc (GRTS), the company’s capital structure generated 0.68 points at debt to capital in total, while cash flow to debt ratio is standing at -2.64. The debt to equity ratio resting at 2.15. The interest coverage ratio of the stock is -52.84.
Currently, EBITDA for the company is -147.04 million with net debt to EBITDA at -0.35. When we switch over and look at the enterprise to sales, we see a ratio of 69.89. The receivables turnover for the company is 8.72for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.54.
Conclusion
In summary, Gritstone Bio Inc (GRTS) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
